Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Based on the strength of the data and the emerging product prole, the analyst forecasts nominal peak sales of ~$2 billion (booked by partner), with Teva booking half the profits.Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA's (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
梯瓦製藥有限公司（紐交所：TEVA）和賽諾菲安萬特（納斯達克：SNY）在其20億RELIEVE UCCD研究中，滿足了對潰瘍性結腸炎（UC）和克羅恩病（CD）患者的主要終點。
In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission compared to 20.45% on placebo, placebo-adjusted rates were 15.7% (low dose) and 27.4% (high dose), at week 14.
在RELIEVE UCCD研究中，接受duvakitug治療的潰瘍性結腸炎患者中，36.2%（低劑量）和47.8%（高劑量）達到了臨床緩解，而安慰劑組爲20.45%，安慰劑調整後的比率爲15.7%（低劑量）和27.4%（高劑量），於第14周時獲得。
BofA Securities raised the price target for Teva to $25 from $23 with a Buy rating, reflecting a strong Phase 2 data update for duvakitug in inflammatory bowel disorders (IBD).
美銀證券將梯瓦的目標股價從23美元上調至25美元，並給予買入評級，這反映了其在炎症性腸病（IBD）方面的強勁二期數據更新。
Based on the strength of the data and the emerging product prole, the analyst forecasts nominal peak sales of ~$2 billion (booked by partner), with Teva booking half the profits.
根據數據的強度和新興產品的檔案，分析師預測名義峯值銷售額約爲20億（由合作伙伴預定），而梯瓦將獲利一半。
Given the anticipated impact on profits by 2030, BofA factors in the long-term strength of Teva's innovative portfolio by applying a valuation multiple of 9.25x to 2025 estimated EV/EBITDA.
考慮到2030年預計對利潤的影響，美銀在評估梯瓦的創新產品組合的長期實力時，以9.25倍的估值倍數應用於2025年預計的企業價值/息稅折舊攤銷前利潤（EV/EBITDA）。
Partnership milestone payments provide reliable cash flow, and the analyst sees potential for the stock to gain value as the company shifts toward growth-focused execution.
合作伙伴的里程碑付款提供可靠的現金流，分析師看到隨着公司向以增長爲導向的執行轉變，股票有潛力增值。
The TL1a drug class has emerged over the last two years, led by Merck & Co Inc (NYSE:MRK) Prometheus' strong Phase 2 data, which was followed by similar data from Roche Holdings AG's (OTC:RHHBY) competitor asset.
TL1a藥物類別在過去兩年中出現，以默沙東爲首（NYSE:MRK）Prometheus的強勁二期數據爲引領，隨後是羅氏控股公司的（場外交易:RHHBY）競爭資產的類似數據。
BofA writes that TL1a was a class of drug that could offer a very good safety profile, on par with market-leading Takeda Pharmaceutical Co Ltd (NYSE:TAK) Entyvio, plus a high rate of efficacy across all major patient subgroups.
美銀寫道，TL1a是一種能夠提供與市場領先的武田製藥（NYSE:TAK）Entyvio相媲美的良好安全性特徵的藥物類別，並且在所有主要患者亞組中都有較高的療效。
Data update from Teva in around 240 patients in Phase 2 showed 16%-27% placebo-adjusted MAYO remission scores in the UC population, with the high dose compared favorably to competitors.
在240名患者的第二階段數據更新中，梯瓦製藥顯示出UC人群的安慰劑調整MAYO緩解評分爲16%-27%，高劑量與競爭者相比表現良好。
TEVA Price Action: Teva Pharmaceutical stock is up 3.23% at $21.56 at publication Wednesday.
梯瓦製藥股價走勢：截至週三出版，梯瓦製藥股票上漲3.23%，報21.56美元。
- Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
- 諾和諾德的Ozempic因潛在增加罕見眼病風險而受到審查。
Photo: Courtey Teva Pharmaceutical Industries
照片：由梯瓦製藥提供
譯文內容由第三人軟體翻譯。
